Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Europe’s CHMP Okays Xtandi, Erivedge And Spedra, But Rejects Xeljanz

This article was originally published in The Pink Sheet Daily

Executive Summary

Two new cancer therapies – Astellas’ prostate cancer drug Xtandi and Roche’s basal cell carcinoma drug Erivedge – have been cleared for European approval by the CHMP scientific advisory panel. It also backed Vivus’ erectile dysfunction therapy Spedra and Avanir’s emotional outburst therapy, Nuedextra, but turned down Pfizer’s JAK inhibitor Xeljanz.

You may also be interested in...



Early Discount Makes Rejection of Astellas’ Xtandi Too Difficult For NICE

By offering an early discount and providing clear clinical effectiveness evidence, Astellas Pharma has propelled its prostate cancer drug Xtandi through U.K.’s NICE.

U.S. Biotechs Strike Out Across Europe

U.S. biotech companies are showing greater interest in building commercial infrastructure in Europe, in order to bring new medicines to European customers without local partners. Switzerland is a popular location, because of its position in the center of the continent, but the presence of experienced management is also important.

Curis Funds Internal Development With Further Erivedge Milestones

The cancer biotech is making strides with its internal pipeline as it continues to earn royalties and collect milestones on its partnered programs.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel